CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
A new Learning Center website will launch on Monday, March 30, 2020. While the link to the new Learn...
CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex...
CTS received notification from Sanochemia Pharmazeutika AG of their intent to immediately discontinu...
FDA Guidance titled “Further Testing of Donations that are Reactive on a Licensed Donor Screen...
We have now added a new section called the "Assay History List" to the "At A Gla...
CTS successfully implemented Donor-Screen HLA® Class I and II testing on the Stratec Biomedical ...